Efficacy of Lenalidomide in Myelodysplastic Syndromes

University of South Florida, Tampa, Florida, United States
New England Journal of Medicine (Impact Factor: 54.42). 03/2005; 352(6):549-57. DOI: 10.1056/NEJMoa041668
Source: PubMed

ABSTRACT Ineffective erythropoiesis is the hallmark of myelodysplastic syndromes. Management of the anemia caused by ineffective erythropoiesis is difficult. In patients with myelodysplastic syndromes and symptomatic anemia, we evaluated the safety and hematologic activity of lenalidomide, a novel analogue of thalidomide.
Forty-three patients with transfusion-dependent or symptomatic anemia received lenalidomide at doses of 25 or 10 mg per day or of 10 mg per day for 21 days of every 28-day cycle. All patients either had had no response to recombinant erythropoietin or had a high endogenous erythropoietin level with a low probability of benefit from such therapy. The response to treatment was assessed after 16 weeks.
Neutropenia and thrombocytopenia, the most common adverse events, with respective frequencies of 65 percent and 74 percent, necessitated the interruption of treatment or a dose reduction in 25 patients (58 percent). Other adverse events were mild and infrequent. Twenty-four patients had a response (56 percent): 20 had sustained independence from transfusion, 1 had an increase in the hemoglobin level of more than 2 g per deciliter, and 3 had more than a 50 percent reduction in the need for transfusions. The response rate was highest among patients with a clonal interstitial deletion involving chromosome 5q31.1 (83 percent, as compared with 57 percent among those with a normal karyotype and 12 percent among those with other karyotypic abnormalities; P=0.007) and patients with lower prognostic risk. Of 20 patients with karyotypic abnormalities, 11 had at least a 50 percent reduction in abnormal cells in metaphase, including 10 (50 percent) with a complete cytogenetic remission. After a median follow-up of 81 weeks, the median duration of transfusion independence had not been reached and the median hemoglobin level was 13.2 g per deciliter (range, 11.5 to 15.8).
Lenalidomide has hematologic activity in patients with low-risk myelodysplastic syndromes who have no response to erythropoietin or who are unlikely to benefit from conventional therapy.

  • Source
    • "The relevant mechanism of action of rituximab is the activation of NK cell-dependent antibody-dependent cellmediated cytotoxicity (ADCC) against leukemia cells [7] [8]. Lenalidomide (Revlimid; Celgene) is an immunomodulatory drug that has shown a clinical effect in several hematological disorders including myeloma [9], myelodysplastic syndrome (MDS) [10], and CLL [11] [12] [13] [14]. Lenalidomide displays a number of pharmacodynamic effects, but the main mechanism of action is not completely known and may vary depending on the disease. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lenalidomide is an immunomodulatory drug with therapeutic activity in chronic lymphocytic leukemia (CLL). However, it has pleiotropic effects, and the mechanism of action responsible for its therapeutic activity has not been well defined yet. Herein, we show that lenalidomide treatment does not have an effect on the proliferation of leukemia cells, but it increases the proliferation of B cells from healthy donors. Lenalidomide did not exert a direct effect on the apoptosis of leukemia cells obtained from CLL patients, although it indirectly induced their apoptosis through the activation of nonmalignant immune cells. Thus, lenalidomide markedly increased the proliferation of NK and CD4 T cells. The effect of lenalidomide on NK cells was secondary to the induction of IL-2 production by CD4 T cells. Accordingly, depletion of T cells or blockade of IL-2 activity completely abrogated the proliferation of NK cells. Additionally, lenalidomide enhanced NK and NKT-like cell-mediated natural cytotoxicity against leukemia cells from CLL patients. Lenalidomide also upregulated CD20 expression on leukemia cells and, accordingly, it had a synergistic effect with rituximab on promoting antibody-dependent cell-mediated cytotoxicity against primary leukemia cells. Overall, these observations provide a support for combining lenalidomide with rituximab as a treatment in CLL.
    BioMed Research International 09/2014; 2014:265840. DOI:10.1155/2014/265840 · 2.71 Impact Factor
  • Source
    • "W grupie otrzymującej 50 mg było znacznie mniej objawów niepożądanych, zwłaszcza powikłań zakrzepowych. Znacznie lepsze wyniki otrzymano , stosując lenalidomid [22]. U chorych z del 5q obserwowano największy odsetek odpowiedzi na leczenie sięgający 83%. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction of new drugs into therapy of multiple myeloma prolonged significantly progression free survival and overall survival of patients. Taking into account pleiotropic effects of these drugs it was shown that immunomodulatory drugs are very effective in other haematological malignancies such as lymphomas, myelodysplastic syndromes, leukemias or chronic myeloproliferative diseases.
    Acta haematologica Polonica 10/2013; DOI:10.1016/j.achaem.2013.06.003
  • Source
    • "Lenalidomide, which possesses pleiotropic properties, belongs to the second generation of immunomodulatory drugs (IMiDs). Lenalidomide and its parental molecule thalidomide have shown therapeutical activity in various malignancies [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lenalidomide is a synthetic compound derived by modifying the chemical structure of thalidomide. It belongs to the second generation of immunomodulatory drugs (IMiDs) and possesses pleiotropic properties. Even if lenalidomide has been shown to be active in the treatment of several hematologic malignancies, this review article is mostly focalized on its mode of action in multiple myeloma. The present paper is about the direct and indirect antitumor effects of lenalidomide on malignant plasmacells, bone marrow microenvironment, bone resorption and host's immune response. The molecular mechanisms and targets of lenalidomide remain largely unknown, but recent evidence shows cereblon (CRBN) as a possible mediator of its therapeutical effects.
    Advances in Hematology 08/2012; 2012:842945. DOI:10.1155/2012/842945
Show more